New PET tracer aims to light up inflammation in joint and muscle diseases

NCT ID NCT03912428

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This early-phase study tested a new radioactive imaging drug called 11C-MC1 to see if it can help detect inflammation in people with rheumatoid arthritis or idiopathic inflammatory myopathy, as well as in healthy volunteers. Participants received PET/CT scans after an injection of the drug, and some also took celecoxib to see if it blocked the signal. The study was terminated early, so its findings are limited, but the goal was to develop a better way to visualize inflammation in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
11C-MC1 (a radioactive imaging drug)
What this could lead to
If it works, this could lead to a better way to see inflammation in the body using PET scans, helping doctors diagnose and monitor conditions like arthritis and myositis.
What could go wrong
This was a very early (Phase 1) study that has already been terminated, so results are limited. The imaging drug is experimental and may not prove useful for routine diagnosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AXIAL SPONDYLOARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.